Objective:To analyze therapeutic effect of rosuvastatin on inflammatory factor levels ,insulin resistance (IR) and vascular endothelial function in patients with hypertension complicated dyslipidemia .Methods:A total of 136 outpatients with hypertension complicated dyslipidemia were selected .According to random number table ,they were divided and equally into routine treatment group (received routine therapy ) and rosuvastatin group (received rosuvastatin based on routine treatment ) .Serum levels of C reactive protein (CRP) ,interleukin‐6 (IL‐6) and IL‐8 , IR and vascular endothelial function were compared between two groups before and after treatment .Results:Com‐pared with before treatment ,there were significant reductions in serum levels of CRP ,IL‐6 and IL‐8 ,homeostasis model‐insulin resistance index (HOMA‐IR) and number of endothelial microparticles (EMPs) ,significant rise in in‐sulin sensitivity index (ISI) and flow‐mediated dilation of brachial artery (FMD) after treatment , P< 0.05 all . Compared with routine treatment group ,there were significant reductions in serum levels of CRP [ (67.27 ± 7.51) mg/L vs .(37.11 ± 6.32) mg/L] ,IL‐6 [ (87.58 ± 7.21)μg/L vs .(60.17 ± 5.45)μg/L] and IL‐8 [ (121.31 ± 8.57)μg/L vs .(84.44 ± 5.21)μg/L] ,HOMA‐IR [ (3.08 ± 0.51) vs .(2.31 ± 0.47)] and number of EMPs [ (852.18 ± 115.37) /μl vs .(573.29 ± 72.18)/μl] ,and significant rise in ISI [(-4.39 ± 0.61) vs .(-3.42 ± 0.53)] and FMD [ (4.35 ± 0.52)% vs .(5.82 ± 0.69)% ] in rosuvastatin group after treatment ,P<0.05 all .Conclusion:Rosuvasta‐tin could reduce inflammatory factor levels ,relieve insulin resistance and improve vascular endothelial function in patients with hypertension complicated dyslipidemia .

Objective:To analyze therapeutic effect of homocysteine (Hcy)‐lowering therapy on serum levels of Hcy and inflammatory factors in patients with coronary heart disease (CHD ) after percutaneous coronary intervention (PCI) .Methods :A total of 82 CHD patients who received PCI in our hospital were selected .According to random number table ,they were randomly and equally divided into routine treatment group (received routine postoperative therapy) and Hcy‐lowering group .Serum levels of Hcy ,inflammatory factors ,N‐terminal pro‐brain natriuretic pep‐tide (NT‐proBNP) and soluble intercellular adhesion molecule‐1 (sICAM‐1) were compared between two groups . Results :1) On six months and one year after treatment ,compared with routine treatment group ,serum Hcy level significantly reduced [after six months: (15.39 ± 1.83) μmol/L vs . (13.21 ± 1.35) μmol/L ,after one year :(15.61 ± 1.62)μmol/L vs . (8.73 ± 0.72)μmol/L] in Hcy‐lowering group ;2) after six‐month treatment ,compared with routine treatment group ,there were significant reductions in serum levels of CRP [ (67.27 ± 7.51) mg/L vs . (37.11 ± 6.32) mg/L] ,IL‐6 [ (87.58 ± 7.21)μg/L vs . (60.17 ± 5.45)μg/L] ,procalcitonin [PCT , (21.34 ± 3.04) ng/L vs .(15.61 ± 2.32) ng/L] ,NT‐proBNP [ (298.37 ± 53.28) pg/ml vs .(104.28 ± 13.17) pg/ml] and sI‐CAM‐1 [ (391.83 ± 75.04) ng/ml vs .(162.18 ± 30.26) ng/ml] in Hcy‐lowering group , P<0.05 all .Conclusion:Hcy‐lowering therapy is help to reduce serum Hcy level ,relieve systemic inflammatory response and protect myocar‐dial function in CHD patients after PCI .

Adenine ; Animals ; Gene Editing ; Mice ; Zygote ; metabolism